Last $0.0058 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

neurokine pharmaceuticals (NEUKF) Snapshot

Open
$0.0031
Previous Close
$0.0058
Day High
$0.0058
Day Low
$0.0031
52 Week High
03/28/14 - $0.04
52 Week Low
04/30/14 - $0.0018
Market Cap
424.9K
Average Volume 10 Days
15.4K
EPS TTM
$0.0020
Shares Outstanding
73.3M
EX-Date
--
P/E TM
3.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROKINE PHARMACEUTICALS (NEUKF)

Related News

No related news articles were found.

neurokine pharmaceuticals (NEUKF) Related Businessweek News

No Related Businessweek News Found

neurokine pharmaceuticals (NEUKF) Details

Neurokine Pharmaceuticals Inc., a development stage company, is engaged in the development and commercialization of therapeutic pharmaceutical products. The company focuses on biologics comprising vaccines, blood, and blood components; allergenics; somatic cells relating to the wall of the body cavity; gene therapy; tissues; and recombinant therapeutics that cause cell death in tumors. Its products under the developmental stage include NK-001 for the potential treatment of neurocognitive impairment in post-coronary artery bypass graft surgery patients; and NK-002 for the potential treatment of Alzheimer’s disease. The company was formerly known as Xerxes Health Corp. and changed its name to Neurokine Pharmaceuticals Inc. in June 2007. Neurokine Pharmaceuticals Inc. was founded in 2002 and is based in Vancouver, Canada.

neurokine pharmaceuticals (NEUKF) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

neurokine pharmaceuticals (NEUKF) Key Developments

Neurokine Pharmaceuticals Inc. Announces Management Changes

On July 24, 2014, Maziar Badii and Richard Azani resigned as directors of Neurokine Pharmaceuticals Inc. The resignations of Maziar Badii and Richard Aazani were not the result of any disagreements with company regarding operations, policies, practices or otherwise. In addition, Hamid Doroudian resigned as president, chief executive officer and secretary. On July 24, 2014, the company appointed Patrick C. Frankham and Hamid Doroudian as directors of company and appointed Ahmad Doroudian, a current director, as president, chief executive officer and secretary. Dr. Frankham has over 18 years of experience in the biopharmaceutical and services industries. Prior to joining Boehringer Ingelheim, he founded several multinational healthcare startup enterprises including healthcare information technology, services and pharmaceuticals companies. Dr. Doroudian was appointed as president, chief executive officer and secretary on August 30, 2011. Dr. Doroudian has over 20 years experience in managing and overseeing clinical research and development of pharmaceutical products. Dr. Doroudian is a founder and owner of Pharmex Rom Industry Ltd. Dr. Doroudian has served as general manager of Pharmex Rom Industry Ltd. since 1992 where his duties have included overseeing all aspects of Pharmex’s business, including clinical research and product development, regulatory affairs, licensing, distribution, and general operations.

Neurokine Pharmaceuticals Deleted From OTCBB

Neurokine Pharmaceuticals Incorporated's ordinary shares has been deleted from OTC Bulletin Board (OTCBB) effective July 17, 2014 on account of its ineligibility for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11.

Neurokine Pharmaceuticals Inc. announced delayed annual 10-K filing

On 05/02/2014, Neurokine Pharmaceuticals Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEUKF:US $0.01 USD 0.00

NEUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEUKF.
View Industry Companies
 

Industry Analysis

NEUKF

Industry Average

Valuation NEUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROKINE PHARMACEUTICALS, please visit www.neurokine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.